GILD (Gilead Sciences, Inc.): Themes, ETFs, and Basket Ideas

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the long-acting prevention drug for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir. More recently, Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generates substantial cash flow from its HIV base, pays a solid dividend, and is investing to diversify into oncology and other areas as it manages future patent expirations.

Risks worth tracking: Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. Hepatitis C revenue declined sharply after its cures shrank the patient pool, illustrating how success can erode markets. Its oncology expansion has been costly and uneven, with some acquired programs underperforming expectations, raising questions about capital allocation. Drug development is risky, with frequent trial failures. The company faces regulatory, reimbursement, and drug-pricing policy pressures, including in the US. Litigation and patent challenges can arise. Diversifying away from virology successfully is essential but unproven at scale, leaving the long-term growth profile dependent on pipeline execution beyond its core HIV business.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Gilead Sciences, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$28 to 30 billion
• Operating margin: ~thirties percent (varies with charges)
• Net income (TTM): ~variable, affected by acquisition charges
• Dividend yield: ~3 to 4%
• Free cash flow: ~strong, several billion annually
• HIV revenue share: ~majority of product sales
• Market cap: ~$100 billion or more

Gilead is valued as a mature, cash-generative biopharma with a dominant HIV base and a solid dividend, rather than a high-growth name. Investors weigh durable virology cash flows and capital return against limited overall growth and uncertainty in oncology. Reported earnings can swing with acquisition-related charges, so investors often focus on underlying product revenue and free cash flow.

The most useful question to ask about a single stock is rarely “will it go up?”. It's “does this fit a thesis I actually believe in, and how do I size it alongside other stocks that fit the same thesis?” That's what Walnut is built for.

Open the AI assistant on Walnut and describe a thesis (for example: “the AI infrastructure buildout”, “dividend growth large-caps”, “global semiconductors”) where GILD would naturally fit. The AI proposes 5 to 6 constituents with target weights, you review, and you can fund the basket through your broker once you're ready.